Jason Napodano, CFA
Managing Director & Sr. Biotech Analyst, Zacks SCR
CFA
Reviewing the $ASTM p2a data set presented at SCAI early today. Very small trial but clearly impressive trends for iDCM patients on ixmy-T.
- About
- Help
- Blog
- Jobs
- Press
- Tools
- Mobile
- Developers
- House Rules
- For Public Companies
- For Market Professionals
-
- Terms
- Privacy
- Disclaimer
- Market Quotes provided by Xignite © 2013 StockTwits, Inc.